1233 studies found for:    LEUKEMIA, CHRONIC MYELOID
Show Display Options
Rank Status Study
1 Completed
Has Results
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Conditions: Chronic Myeloid Leukemia;   Philadelphia-Positive Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Imatinib
2 Completed
Has Results
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
Conditions: Chronic Myeloid Leukemia;   Philadelphia-Positive Myeloid Leukemia
Intervention: Drug: Dasatinib
3 Completed
Has Results
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
Conditions: Leukemia;   Chronic Myelogenous Leukemia;   Chronic Myeloid Leukemia
Intervention: Drug: Interleukin-11  (IL-11 or Neumega)
4 Completed
Has Results
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Essential Thrombocythemia;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Polycythemia Vera;   Primary Myelofibrosis;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: fludarabine phosphate;   Drug: triapine;   Procedure: laboratory biomarker analysis
5 Active, not recruiting Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed By Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Biological: therapeutic allogeneic lymphocytes;   Other: laboratory biomarker analysis
6 Completed Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy
Condition: Chronic Myeloid Leukemia
Intervention: Biological: Autologous CIK cell infusion
7 Terminated Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate;   Drug: temsirolimus;   Other: laboratory biomarker analysis
8 Completed Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate;   Drug: decitabine;   Other: laboratory biomarker analysis
9 Completed PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
Conditions: Adult Acute Promyelocytic Leukemia (M3);   Blastic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia
Intervention: Drug: bortezomib
10 Completed Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Conditions: Childhood Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: omacetaxine mepesuccinate;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Active, not recruiting Patient Reported Outcomes in Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: HRQOL questionnaire
12 Terminated Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: dasatinib;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study;   Drug: cyclosporine
13 Completed STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate;   Drug: cytarabine
14 Completed Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib, interferon-alfa
15 Completed Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase Chronic Myelogenous Leukemia;   Relapsing Chronic Myelogenous Leukemia
Interventions: Biological: oblimersen sodium;   Drug: imatinib mesylate;   Other: laboratory biomarker analysis
16 Unknown  A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: dasatinib
17 Recruiting Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Other: Echo, exercise echo, and if indicated, right heart catheter
18 Recruiting Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Dasatinib discontinuation
19 Active, not recruiting Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Nilotinib
20 Recruiting Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Conditions: Chronic Phase Philadelphia Positive;   BCR-ABL Positive;   Chronic Myeloid Leukaemia
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years